0.05Open0.05Pre Close6 Volume925 Open Interest2.50Strike Price30.00Turnover274.22%IV147.57%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1739Delta0.3619Gamma20.60Leverage Ratio-0.0039Theta0.0001Rho3.58Eff Leverage0.0007Vega
Renovaro Stock Discussion
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
Monday, 23rd December at 9:00 am
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary RenovaroCube (the...
Renovaro Regains Compliance with NASDAQ Listing Requirement
Friday, 20th December at 3:40 pm
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requireme...
Renovaro focuses on AI-driven healthcare innovation, particularly in early cancer detection and immunotherapy. Their flagship product, RenovaroCube, uses AI for diagnostics. The company has also acquired GEDi Cube and formed partnerships with institutions like Amsterdam UMC Cancer Center. Recent restructuring includes appointing David Weinstein as CEO .
2. $Rigetti Computing (RGTI.US)$Rigetti Co...
keeping my eyes on this one
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
RenovaroCube (NASDAQ: RENB), a leader in AI-driven cancer diagnostics, presented groundbreaking research at the Molecular Analysis for Precision Oncology Congress on October 16, 2024. The study explores the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) from blood plasma to detect copy number alterations (CNAs) in lung cancer patients.
Key findi...
No comment yet